Gastrointestinal Cancer

Christopher Crane, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the role of radiation in the treatment of gastrointestinal malignancies.

Ghassan K. Abou-Alfa, MD, discusses what he sees coming down the pike in epatocellular carcinoma with regard to novel agents, including CAR T-cell therapy, and the burgeoning questions with optimal sequencing of these treatments.

Leonard Saltz, MD, discusses current go-to therapies and overarching questions for mCRC treatment.

William R. Jarnagin, MD, discusses the necessary role of surgery and novel techniques in patients with colorectal cancer.

The European Union’s CHMP has delivered a positive opinion for Herzuma (CT-P6), a trastuzumab (Herceptin) biosimilar in HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses pembrolizumab (Keytruda) in colorectal cancer.

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early stage pancreatic cancer.

Pembrolizumab did not improve survival as a second-line treatment for PD-L1–positive patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to findings from the phase III KEYNOTE-061 trial.

Nancy E. Kemeny, MD, a medical oncologist at Memorial Sloan Kettering Cancer Institute, discusses liver-directed therapies for patients with metastatic colorectal cancer (CRC).

Shubham Pant, MD, stresses the importance of clinical trials as an avenue to establish more novel treatment decisions in colorectal cancer.

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the responses seen with microsatellite-instability high (MSI-H) and NTRK fusions in patients with gastrointestinal cancer.

Mutations in the BRAF kinase are found in a relatively small number of patients with metastatic colorectal cancer, but they nonetheless have important implications for prognosis and response to standard therapy.

Leonard Saltz, MD, Executive Director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses chemotherapy for patients with metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, FACP, and Rona D. Yaeger, MD, discuss the current treatment landscape and other key issues relating to this distinct subset of colorectal cancer.

Adding ramucirumab to cisplatin and capecitabine or 5-FU in the frontline setting did not improve overall survival in patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma, according to topline results from the phase III RAINFALL trial.

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).

Michael Pishvaian, MD, PhD, discusses the progress that has been made in the treatment of patients with pancreatic cancer during the 2017 Ruesch Center Symposium.

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the current state of RAS-mutant gastrointestinal (GI) cancers during the 2017 Ruesch Center Symposium.

A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses integrating immunotherapy into the treatment landscape of colorectal cancer (CRC).